Early-stage
Thuja et al. invest €2.4m in Therasolve
VC was joined by business angels in the round
Kernel et al. invest €2m in Hibergene
Company will use the funds to commercialise its first two products
BMT backs Oncgnostics series-A
HTGF initially provided seed funding in 2012
Atlas Genetics raises $20m
Company will launch first testing product later this year
Northzone leads $2.8m round for Fuse
Fresh capital brings total amount raised by software company to $7m
DACH region suffers activity slump in 2014
DACH deal volume has dropped to its lowest position since 2002
Capricorn et al. invest €1.3m in Feops
Funding will be used to launch company's first product in Europe and US
Sequoia leads $1.5m seed round for Mapillary
Playfair, Wellington and LDV Capital take part in round
Seroba et al. invest £18m in Veryan
Company plans on commercialising its product later this year
Sunstone et al in €20m series-B for Orphazyme
Total funding for Orphazyme reaches тЌ34m with latest round
Thuja et al. invest in Hemics
Company plans to commercialise HandScan product
Seventure backs MaaT
Firm commits to invest further €1m based on milestones
Miracor raises €4.5m series-B extension
€7m series-B took place in September 2011
NeoMed leads CHF 20m Genkyotex financing
VI Partners and BioMedInvest are co-investors
Oxford Tech in £2m round for Lightpoint
Several business angel networks also participated in the round
Thuja et al. invest €6m in Cristal
Company will use funds to launch first clinical study of anti-cancer nanomedicine
HTGF backs Multiphoton Optics
Commitments also came from Fraunhofer Venture and private investor Boris Neubert
Optomeditech raises $2.5m from Lifeline and Sitra
Company is preparing for its commercial launch
Corporate venture profits in Russia
Geopolitical headwinds not deterring corporate venture investors in Russia
HTGF invests in All3DP
News and design website aims to capitalise on recent 3D printing trend
BioMedPartners and Grazia back Ayoxxa
Additional investment brings funding round to €11.3m
Pieris raises fifth funding round
Company previously raised €43m in growth capital
LSP-HEF co-leads Curetis's series-B extension
Molecular diagnostics company has raised €63.5m since inception
Vesalius et al. invest €20m in Promethera
Company recently completed phase-I/II trials of its HepaStem product